Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


A NanoBRET-based binding assay for Smoothened allows real time analysis of ligand binding and distinction of two binding sites for BODIPY-cyclopamine.

Kozielewicz P, Bowin CF, Turku A, Schulte G.

Mol Pharmacol. 2019 Nov 9. pii: mol.119.118158. doi: 10.1124/mol.119.118158. [Epub ahead of print]


Molecular Pharmacology of Class F Receptor Activation.

Kozielewicz P, Turku A, Schulte G.

Mol Pharmacol. 2019 Oct 7. pii: mol.119.117986. doi: 10.1124/mol.119.117986. [Epub ahead of print]


Asymmetry in catalysis by Thermotoga maritima membrane-bound pyrophosphatase demonstrated by a nonphosphorus allosteric inhibitor.

Vidilaseris K, Kiriazis A, Turku A, Khattab A, Johansson NG, Leino TO, Kiuru PS, Boije Af Gennäs G, Meri S, Yli-Kauhaluoma J, Xhaard H, Goldman A.

Sci Adv. 2019 May 22;5(5):eaav7574. doi: 10.1126/sciadv.aav7574. eCollection 2019 May.


Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors.

Turku A, Leino TO, Karhu L, Yli-Kauhaluoma J, Kukkonen JP, Wallén EAA, Xhaard H.

ChemMedChem. 2019 May 6;14(9):965-981. doi: 10.1002/cmdc.201900074. Epub 2019 Apr 2.


Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26.

Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EAA, Kukkonen JP.

Eur J Pharmacol. 2018 Oct 15;837:137-144. doi: 10.1016/j.ejphar.2018.09.003. Epub 2018 Sep 5.


Defining Dynamics of Membrane-Bound Pyrophosphatases by Experimental and Computational Single-Molecule FRET.

Harborne SPD, Strauss J, Turku A, Watson MA, Tuma R, Harris SA, Goldman A.

Methods Enzymol. 2018;607:93-130. doi: 10.1016/bs.mie.2018.04.017.


Azulene-based compounds for targeting orexin receptors.

Leino TO, Turku A, Yli-Kauhaluoma J, Kukkonen JP, Xhaard H, Wallén EAA.

Eur J Med Chem. 2018 Sep 5;157:88-100. doi: 10.1016/j.ejmech.2018.07.040. Epub 2018 Jul 20.


Scaffold hopping from (5-hydroxymethyl) isophthalates to multisubstituted pyrimidines diminishes binding affinity to the C1 domain of protein kinase C.

Provenzani R, Tarvainen I, Brandoli G, Lempinen A, Artes S, Turku A, Jäntti MH, Talman V, Yli-Kauhaluoma J, Tuominen RK, Boije Af Gennäs G.

PLoS One. 2018 Apr 11;13(4):e0195668. doi: 10.1371/journal.pone.0195668. eCollection 2018.


Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity.

Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP.

PLoS One. 2017 Jun 2;12(6):e0178526. doi: 10.1371/journal.pone.0178526. eCollection 2017.


Insights into the mechanism of membrane pyrophosphatases by combining experiment and computer simulation.

Shah NR, Wilkinson C, Harborne SP, Turku A, Li KM, Sun YJ, Harris S, Goldman A.

Struct Dyn. 2017 Mar 3;4(3):032105. doi: 10.1063/1.4978038. eCollection 2017 May.


Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands.

Turku A, Borrel A, Leino TO, Karhu L, Kukkonen JP, Xhaard H.

J Med Chem. 2016 Sep 22;59(18):8263-75. doi: 10.1021/acs.jmedchem.6b00333. Epub 2016 Sep 8.


Modeling of the OX1R-orexin-A complex suggests two alternative binding modes.

Karhu L, Turku A, Xhaard H.

BMC Struct Biol. 2015 May 9;15:9. doi: 10.1186/s12900-015-0036-2.

Supplemental Content

Support Center